| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02139280 | Hematologic Malignancies | Drug: Cyclophosphamide | Dartmouth-Hitchcock Medical Center | Phase 2 | 2013-12-01 | 2016-11-02 |
| NCT00501995 | Scleroderma | Drug: IV Cyclophosphamide | Johns Hopkins University | Phase 3 | 2001-02-01 | 2016-08-29 |
| NCT01836289 | Crohn's Disease|Crohn Disease | Drug: High-dose Cyclophosphamide | Johns Hopkins University | Phase 1|Phase 2 | 2015-03-01 | 2015-03-01 |
| NCT01630538 | Antibody Mediated Rejection | Drug: Cyclophosphamide | University of Manitoba | Phase 2 | 2013-06-01 | 2016-10-24 |
| NCT02389309 | Solid Tumors | Drug: Dasatinib|Drug: Cyclophosphamide|Drug: Temsirolimus | M.D. Anderson Cancer Center | Phase 1 | 2015-10-05 | 2017-03-07 |
| NCT00412243 | Burkitt's Lymphoma|Lymphoblastic Lymphoma|Acute Lymphoblastic Leukemia | Drug: Clofarabine|Drug: Cyclophosphamide | M.D. Anderson Cancer Center|Genzyme, a Sanofi Company | Phase 1|Phase 2 | 2006-03-01 | 2013-03-08 |
| NCT02444091 | Chronic Fatigue Syndrome (CFS)|Myalgic Encephalomyelitis (ME) | Drug: Cyclophosphamide | Haukeland University Hospital|The Kavli Foundation|Oslo University Hospital | Phase 2 | 2015-03-01 | 2016-04-11 |
| NCT01352338 | Multiple Myeloma | Drug: Lenalidomide, endoxan, prednisone|Drug: lenalidomide, endoxan, prednisone | UMC Utrecht|Celgene Corporation | Phase 1|Phase 2 | 2011-08-01 | 2016-02-25 |
| NCT00981708 | Amyloidosis | Drug: Lenalidomide, Dexamethasone and Cyclophosphamide | University of Athens|Hellenic Cooperative Oncology Group | Phase 1|Phase 2 | 2008-02-01 | 2014-01-30 |
| NCT01974518 | Pemphigus | Drug: Rituximab and Cyclophosphamide IV | Uprety Shraddha|Postgraduate Institute of Medical Education and Research | Phase 3 | 2013-11-01 | 2014-10-29 |
| NCT02794077 | Recurrent Nasopharyngeal Undifferentiated Carcinoma|Stage IV Nasopharyngeal Undifferentiated Carcinoma | Drug: Cyclophosphamide | The University of Hong Kong | Phase 2 | 2008-01-01 | 2016-06-02 |
| NCT01995331 | Aplastic Anemia | Drug: cyclophosphamide,cyclosporine A | Xiaofan Zhu|Chinese Academy of Medical Sciences | Phase 4 | 2012-03-01 | 2013-11-21 |
| NCT02013336 | Recurrent or Refractory Solid Tumors|Ewing Sarcoma|Rhabdomyosarcoma|Neuroblastoma|Osteosarcoma | Drug: MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide | South Plains Oncology Consortium | Phase 1 | 2013-12-01 | 2017-02-02 |
| NCT00890955 | Lung Cancer | Drug: Amrubicin|Drug: Cyclophosphamide | Lawrence Einhorn|Celgene Corporation|Hoosier Cancer Research Network | Phase 1 | 2009-03-01 | 2015-12-21 |
| NCT01207297 | SLE|Lupus Nephritis|Renal Insufficiency|End-stage Renal Disease | Drug: Tacrolimus|Drug: cyclophosphamide | Zhejiang University | Phase 1 | 2003-03-01 | 2011-08-22 |
| NCT01740401 | Melanoma | Drug: Cyclophosphamide, Ipilimumab | Icahn School of Medicine at Mount Sinai|Bristol-Myers Squibb | Phase 2 | 2012-10-01 | 2015-01-06 |
| NCT01910844 | Metastatic Breast Cancer | Drug: Cisplatin|Drug: Cyclophosphamide | Centre Jean Perrin | Phase 2 | 2013-07-01 | 2016-10-10 |
| NCT02441491 | ROHHAD Syndrome | Drug: Cyclophosphamide | Sidney Kimmel Comprehensive Cancer Center | | 2015-03-01 | 2016-05-17 |
| NCT00176605 | Prostate Cancer | Drug: Etoposide|Drug: Cyclophosphamide | Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Bristol-Myers Squibb | Phase 2 | 2005-05-01 | 2014-04-18 |
| NCT00844506 | Ovarian Cancer | Drug: P53-SLP vaccine|Drug: Cyclophosphamide | University Medical Center Groningen|ISA Pharmaceuticals B.V.|Dutch Cancer Society | Phase 2 | 2008-10-01 | 2011-02-24 |
